Redwood City, California–based Earli is, in many ways, a quintessential Silicon Valley startup. As is often the case, there’s not only a Stanford connection but a grand ambition. The company is developing a “synthetic biopsy” platform that aims to detect cancer at its earliest stages by programming cancer cells to reveal themselves and even self-destruct.…
ChatRWD outperforms tech giants in medical question-answering
When it comes to medical AI, the biggest names aren’t necessarily delivering the best results. While tech giants race to build ever-larger language models, a new preprint reveals that when it comes to clinical accuracy and physician trust, a smaller player is outperforming the industry heavyweights. Putting large language model-based systems to the test Researchers…
How ConcertAI and NVIDIA’s AI tools are architecting faster and smarter cancer trials
Imagine tripling or quadrupling the speed at which eligible patients are matched to potentially life-saving cancer trials. That’s the promise of ConcertAI’s AI-powered screening technology, which demonstrated a 3 to 4 times efficiency gain over traditional EMR-based methods in a recent study presented at the American Society of Clinical Oncology (ASCO) conference. Focusing on relapsed…
The 100 best-funded biotech companies from 2015 to present
In early 2022, secretive Altos Labs emerged with a sizable $3 billion launch to pursue anti-aging “cellular rejuvenation” amid rumors of Jeff Bezos’ backing. The company is the best-funded biotech in recent memory. But looking back to 2015 to present, the best funded company is Grail, which developed a multi-cancer early detection test but faced major…
Clinical trials have a diversity Problem. Real-world data could be part of the solution
While diversity in clinical trials has won attention in recent years, uneven representation of diverse populations in clinical trials remains a core barrier to global healthcare equity. Real-world data (RWD) paired with artificial intelligence techniques can almost instantly analyze how well drugs work in diverse subpopulations once they hit the market. RWD can also help…
Anosmia to amyloidosis: nference’s AI is decoding healthcare data at scale
The complexity of patient records, with their mix of unstructured notes and diverse data types, defies traditional analysis. While a thorough review of even a single patient’s file can be tedious for a human, AI tools offer the power to analyze tens or even hundreds of millions of records, unlocking data patterns that would otherwise…
Devices, disease, and digital: Holy Grail of healthcare AI
In episode 3 of AI Meets Life Sci, DeviceTalks Managing Editor Kayleen Brown and Pharma and Biotech Editor Brian Buntz sit down with GE HealthCare GM of Oncology Ben Newton and Haley Schwartz of Catalyze Healthcare to discuss the impacts of AI to screen, diagnose, prognose, and treat cure disease while addressing real-world implementation issues from regulation and liability to clinician trust and adoption. They review the AI…
Wrangling medical imaging data: Strategies to streamline AI-powered workflows
The value of artificial intelligence (AI) and machine learning (ML) in medical imaging is undeniable: more accurate diagnoses, predictive insights and streamlined workflows. However, as Big Pharma and medical research institutions amplify their AI and ML endeavors, they confront pivotal challenges. Chief among these challenges are the intricacies of labeling and annotating medical images. Approximately…
Microsoft and 1910 Genetics are discovering health data’s hidden gems: Here’s how
In episode 2 of AI Meets Life Sci, DeviceTalks Managing Editor Kayleen Brown, and Pharma Editor Brian Buntz explore how Big Tech is developing artificial intelligence (AI) infrastructure in a variety of healthcare organizations. Elena Bonfiglioli, global business leader for Health and Life Sciences at Microsoft, weighs in on the subject, also sharing that she…
Unlocking generative AI requires reshaping culture, operations, and talent dynamics
In drug discovery and development, generative AI and natural-language processing (NLP) tools promise more than incremental productivity gains. For companies that can integrate such tools strategically into their workflows, the tools open the door to a fundamental rethinking of operational processes. For instance, generative AI tools can accelerate drafting of research articles, novel target identification,…
How the latest AI executive order might impact drug development in the U.S.
The White House has released an executive order that contains what it hails as “the most sweeping actions ever taken to protect Americans from the potential risks of AI systems.” Relevant to drug development, a fact sheet on the order describes its aim to help further “the responsible use of AI in healthcare and the…
CEO: Insilico on how AI can ‘imagine the perfect molecules’ for drug targets
Insilico Medicine, an AI-based biotech startup, announced details of their first AI-designed drug candidate to enter human clinical trials. INS018_055 is an experimental treatment for idiopathic pulmonary fibrosis, a rare lung disease. Through their Insilico AI-driven drug discovery platform, they discovered and designed INS018_055 in just 30 months, significantly faster than the industry average. Phase…
8 considerations to boost clinical trial productivity with AI while dodging hallucination hurdles
The development of new drugs is undeniably a data-intensive endeavor. Despite impressive advances in AI over the past years, researchers often continue to grapple with crushing data volumes. This hurdle is particularly apparent in clinical trials, where crucial data is often stored in machine-unfriendly formats such as PDFs, PowerPoint or HTML or other formats. This article explores…
UBS: Generative AI is no silver bullet for drug discovery
Imagine a world where the process of developing life-saving drugs is as streamlined as a modern assembly line. In such a reality, generative AI in drug discovery might churn out promising compounds with similar efficiency and precision as a factory robot assembling a car. Moreover, such technology could chip away at the steep cost and…
A current perspective on machine learning’s role in advancing clinical trials diversity
The year 2020 was a watershed moment for many reasons, but notably, it cast a light on the pervasive health and social inequities that have long marred the U.S. The COVID-19 pandemic hit diverse populations disproportionately hard, as Deloitte and others have noted. Additionally, the tragic deaths of George Floyd, Breonna Taylor and others provoked…
Decoding the enigma of the commander complex: Employing AlphaFold2 to illuminate biological structures
Machine learning algorithms, such as Alphabet’s neural network-based model AlphaFold2, are steadily transforming medical research, shedding light on complex biological structures. A recent case in point involves research using the technology to explore the Commander complex, a 16-protein complex crucial for cellular protein transport processes. This complex is not only vital for normal cellular function,…
BenevolentAI is pioneering AI-driven drug discovery methods
“Can we treat chronic inflammation in ulcerative colitis by reversing immune cell activation in colonic mucosa?” That’s an example of a biological question that the AI-enabled drug discovery firm BenevolentAI (AMS:BAI) would ask when exploring a new drug target. Incorporating a disease, sign, mechanism and tissue into a single question provides focal points for the…